Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
AZA Combined With NAC for PIT After HSCT
- Conditions
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2021-11-18
- Target Recruit Count
- 100
- Registration Number
- NCT05126004
- Locations
- 🇨🇳
The first affiliated hospital of Soochow University, Suzhou, Jiangsu, China
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT05107856
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 378
- Registration Number
- NCT05079230
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UC Irvine Health- Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸The University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT05074355
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 30
- Registration Number
- NCT05053425
- Locations
- 🇨🇳
Long Zhao, Lanzhou, Gansu, China
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 30
- Registration Number
- NCT05042531
- Locations
- 🇨🇳
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 37
- Registration Number
- NCT05008666
- Locations
- 🇨🇳
Department of Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 160
- Registration Number
- NCT04980885
- Locations
- 🇨🇳
The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Brian Jonas
- Target Recruit Count
- 16
- Registration Number
- NCT04964505
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Kahr Medical
- Target Recruit Count
- 36
- Registration Number
- NCT04937166
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.